Considering this experimental evidence [14,277,278,279,280,281,282], two recent expert documents strongly suggest that hs-cTnI and hs-cTnT should be measured in the general population to detect early symptomatic individuals at higher risk of progressing to symptomatic HF or developing MACE over ≥6 months, such as patients aged >55 years and with comorbidities [15,16]. This evidence concerns the gene TNNI3 and hydrops fetalis.